Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 5, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Gastric AdenocarcinomaGastro-esophageal Junction Adenocarcinoma

Interventions

DRUG

Adebrelimab, Nab-paclitaxel, Oxaliplatin, Tegafur Gimeracil Oteracil Potassium Capsule

Adebrelimab combined with Nab-paclitaxel, Oxaliplatin andTegafur Gimeracil Oteracil Potassium Capsule

Trial Locations (1)

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER